How (TVTX) Movements Inform Risk Allocation Models
This article analyzes Travere Therapeutics Inc. (NASDAQ: TVTX) using AI models, identifying weak near- and mid-term sentiment but a strong long-term outlook. It outlines three trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal strengths and support/resistance levels to inform risk allocation decisions for TVTX.
Travere Therapeutics, Inc. (TVTX) stock price, news, quote and history
This article provides a comprehensive overview of Travere Therapeutics, Inc. (TVTX) stock, including its current price, historical data, and financial performance. It details the company's biopharmaceutical focus on rare kidney and metabolic diseases, highlighting key products like FILSPARI and clinical-stage programs. The report also includes analyst insights, earnings trends, and valuation measures.
Travere Therapeutics (TVTX) to Present New FILSPARI Data at ASN Kidney Week 2026
Travere Therapeutics (TVTX) is set to present nine new studies on its drug FILSPARI at ASN Kidney Week 2026, highlighting promising results for treating IgA nephropathy and FSGS. Despite positive clinical data, the company's stock trades at a high Price-to-Sales ratio of 9.16, indicating significant market expectations for future growth, while it remains unprofitable with weak financial strength. Insider selling activity suggests caution, although six gurus hold shares.
Investigation launched into Travere Therapeutics officers for possible self-dealing harming shareholders
Kuehn Law, PLLC has initiated an investigation into the officers and directors of Travere Therapeutics for potential breaches of fiduciary duties through self-dealing. This probe aims to uncover possible harm to shareholders and may lead to legal damages and governance reforms. Long-term investors are urged to contact the law firm to protect their rights and address concerns regarding corporate governance.
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
Kuehn Law is encouraging investors of Travere Therapeutics, Inc. (TVTX) to contact their law firm. This announcement from PR Newswire contains only a headline and no further details regarding the nature of the encouragement or potential legal actions.
Travere Therapeutics (TVTX) Secures FILSPARI Patent Extension, Is The Stock A Bargain?
Travere Therapeutics (TVTX) recently secured a patent extension for its drug FILSPARI, now protected until October 2037 for focal segmental glomerulosclerosis. Despite mixed short-term stock performance, the company shows strong long-term sentiment and is considered 19% undervalued by many, with a fair value pegged at $74.14. However, a different valuation perspective, using sales multiples, suggests the stock might be richly priced compared to peers, indicating less room for error if the FILSPARI thesis faces challenges.
Travere Therapeutics Inc. (TVTX) Key Financial Ratios – Valuation, Profitability & More
This article provides a detailed analysis of Travere Therapeutics Inc. (TVTX) through its key financial ratios across valuation, profitability, growth, solvency, and operating efficiency. It presents both quarterly and annual data, including comparisons against peer medians for various metrics. The report highlights the company's performance in revenue, EBIT, net profit, and EPS growth, alongside solvency and efficiency ratios for investors.
RTRX5376243 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the RTRX5376243 bond issued by Travere Therapeutics, Inc. It outlines key bond details such as issuer information, issue and maturity dates, face value, and credit risk assessment. The bond profile also includes information on interest payments, specifically the 2.25% semi-annual fixed-rate coupon, and lists upcoming payout schedules.
CEO Change Could Be A Key Moment For Travere Therapeutics Stock (TVTX)
Travere Therapeutics (TVTX) is undergoing a significant leadership change with Bradley Campbell taking over as CEO and President in December 2026. This coincides with a USPTO Notice of Allowance for a FILSPARI patent, extending its protection for focal segmental glomerulosclerosis until October 2037. These developments raise questions about the company's strategy for balancing execution risk with protecting a key asset, especially given its existing approvals for IgA nephropathy and FSGS.
Travere Therapeutics appoints new CEO Bradley Campbell
Travere Therapeutics announced that President and CEO Eric Dube will step down effective December 1, 2026. Bradley L. Campbell, former CEO of Amicus Therapeutics, has been appointed as his successor. Campbell's compensation package includes a $1 million base salary, substantial bonus eligibility, and approximately $16.5 million in inducement equity grants.
Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI
Travere Therapeutics announced it has received a US patent allowance for its kidney disease drug, FILSPARI. This development was reported by MT Newswires. The full article is behind a premium paywall.
Travere receives patent allowance for FILSPARI use in FSGS
Travere Therapeutics Inc. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering certain methods of using its drug FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS). This patent is expected to provide U.S. coverage for FILSPARI in FSGS until October 2037. The company plans to list the patent in the FDA's Orange Book, further securing its intellectual property for the rare disease treatment.
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
Travere Therapeutics announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application covering methods of using FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). This patent is expected to provide U.S. coverage until October 2037 and will be listed in the FDA's "Orange Book." The company also recently received a separate U.S. patent for sparsentan's use in IgA nephropathy.
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
Travere Therapeutics announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering certain methods of using FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS). This patent is expected to provide U.S. coverage until October 2037 and will be listed in the FDA's "Orange Book." The company also recently received a patent for sparsentan's use in IgA nephropathy (IgAN).
Why Everyone Is Watching Travere Therapeutics (TVTX) Today
Travere Therapeutics (TVTX) is experiencing investor focus due to an upcoming leadership change, with CEO Eric Dube stepping down on December 1, 2026. The stock currently trades at a significant discount to analyst targets and fair value estimates, driven by the potential expansion of its drug Filspari's label to treat FSGS. While the company shows strong long-term shareholder returns, its future relies heavily on the success of Filspari, posing both opportunity and execution risks.
Travere Therapeutics Announces Planned Chief Executive Officer Transition
Travere Therapeutics announced that its President and CEO, Eric Dube, Ph.D., will step down in December 2026 for health and family reasons. Bradley L. Campbell, former president and CEO of Amicus Therapeutics, has been appointed as his successor, effective December 1, 2026. Dr. Dube will remain as an executive advisor until February 15, 2027, to ensure a smooth transition.
Travere Therapeutics Names Bradley Campbell CEO
Travere Therapeutics announced that Bradley L. Campbell, former president and CEO of Amicus Therapeutics, will succeed Eric Dube as president and CEO, effective December 1, 2026. Dube, who led Travere's evolution into a rare disease company and achieved significant regulatory approvals, will remain an executive advisor until February 15, 2027, to ensure a smooth transition. Campbell brings over 25 years of biopharmaceutical experience, with a strong focus on rare diseases, and aims to build on Travere's momentum and expand its reach to more patients.
Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today
Travere Therapeutics (TVTX) stock has seen significant price gains, leading to questions about its current valuation relative to revenue. While the stock's P/S ratio is lower than the biotech industry average, a "Fair Ratio" model suggests it might be overvalued based on growth outlook, margins, size, and risk. Analysts present both bull and bear cases, focusing on FILSPARI's potential and reliance on the product, respectively.
Travere Therapeutics stock falls amid CEO transition news
Travere Therapeutics Inc. (NASDAQ:TVTX) shares fell in after-hours trading following the announcement of CEO Eric Dube's departure in December 2026 due to health and family reasons. Bradley L. Campbell, former president and CEO of Amicus Therapeutics, will succeed Dube, bringing over 25 years of biopharmaceutical experience to the role. Dube, who led the company through significant regulatory approvals, will remain as an executive advisor during the transition.
Travere Therapeutics Announces Planned Chief Executive Officer Transition
Travere Therapeutics announced that its President and CEO, Eric Dube, Ph.D., will step down in December 2026 due to personal health and family reasons after eight years of leadership. Bradley L. Campbell, former president and CEO of Amicus Therapeutics, will succeed him, effective December 1, 2026. Dube will remain as an executive advisor until February 2027 to ensure a smooth transition, as Campbell aims to build on Travere's momentum in rare disease therapies.
Travere Therapeutics President and CEO Eric Dube Plans to Step Down
Travere Therapeutics (TVTX) announced that its President and CEO, Eric Dube, plans to step down. The information was released late Monday by MT Newswires. Further details regarding Dube's departure are available to premium subscribers.
Travere Therapeutics Insider Sold Shares Worth $25,390,729, According to a Recent SEC Filing
An insider at Travere Therapeutics sold shares valued at $25,390,729, as reported in a recent SEC filing. The article, published on September 18, 2026, by MT Newswires, provides this specific transaction detail among other insider sales for the company. Travere Therapeutics is a biopharmaceutical firm focused on rare kidney and metabolic diseases.
Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock
Peter Heerma, EVP and CCO at Travere Therapeutics (NASDAQ:TVTX), sold approximately $17.86 million worth of company stock through a pre-arranged trading plan between September 15-17, 2026. Concurrently, he acquired about $4.05 million in common stock by exercising employee options. These transactions occurred as TVTX shares approached a 52-week high, with the stock deemed overvalued by InvestingPro analysis, despite the company reporting strong Q2 2026 revenue driven by its kidney drug, FILSPARI.
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
Travere Therapeutics, Inc. (Nasdaq: TVTX) announced that its management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET. A live webcast of the presentation will be available on the Investor page of Travere’s website, with a replay accessible for up to 30 days. The company, a biopharmaceutical firm focused on rare diseases, aims to develop and deliver life-changing therapies to patients and caregivers.
Travere Therapeutics (NASDAQ: TVTX) shareholder Eric Dube plans 95,666-share sale in September 2026
Travere Therapeutics (TVTX) board member Eric Dube plans to sell 95,666 shares of the company's common stock, valued at approximately $6.3 million, on September 15, 2026. This sale is being conducted under Rule 144 through Morgan Stanley Smith Barney LLC and is tied to the exercise of stock options for cash. The filing details the transaction and includes key figures such as the number of shares and aggregate market value.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics announced that its Board of Directors' Compensation Committee granted inducement equity awards to 16 new employees. These grants, totaling 56,220 restricted stock units (RSUs), are an inducement for their employment under Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on continued employment.
Travere Therapeutics stock hits 52-week high at 68.25 USD
Travere Therapeutics (TVTX) stock reached a new 52-week high of $68.25, marking a significant 172.32% increase over the past year due to strong investor confidence and 77% revenue growth. The company's kidney drug, FILSPARI, has been a key driver, with second-quarter revenue exceeding forecasts at $169.6 million. Despite appearing overvalued, analysts predict profitability for TVTX this year.
FDA issues Untitled Letter to Travere Therapeutics over visual aid for kidney disease drug Filspari
The FDA's Office of Prescription Drug Promotion has issued an Untitled Letter to Travere Therapeutics concerning its visual aid for the kidney disease drug, Filspari. The agency claims that several statements in the visual aid, intended for physicians, are misleading as they are not supported by clinical data. The FDA highlighted issues with claims regarding "kidney preservation," "complete remission of proteinuria," and the drug being "well tolerated," demanding a response from Travere Therapeutics within 15 working days.
Travere Therapeutics stock hits 52-week high at 67.97 USD By Investing.com
Travere Therapeutics (NASDAQ: TVTX) stock has reached a new 52-week high of $68.03, reflecting a 243% 1-year return. This surge is attributed to strong investor confidence and the impressive performance of its kidney drug, FILSPARI, which contributed significantly to the company's Q2 revenue of $169.6 million. Analyst firm Stifel raised its price target for TVTX to $62, maintaining a Hold rating, following FILSPARI's strong initial quarter post-FSGS launch.
Travere Therapeutics stock hits 52-week high at 67.97 USD
Travere Therapeutics (TVTX) stock recently hit a 52-week high of $68.03, reflecting a 243% 1-year return, driven by strong investor confidence and impressive Q2 revenue of $169.6 million. This performance was significantly boosted by high demand for its kidney drug, FILSPARI, leading Stifel to raise its price target to $62. The stock is currently trading above its Fair Value according to InvestingPro data, signaling strong future growth expectations.
Travere Therapeutics CFO Christopher R. Cline Executes 642-Share Sale for Tax Withholding on RSU Vesting
Christopher R. Cline, CFO of Travere Therapeutics, sold 642 shares of common stock on September 2, 2026, at $66.37 per share. This transaction was not a discretionary trade but a mandatory "sell to cover" to fulfill tax withholding obligations arising from vested restricted stock units. Following the sale, Cline beneficially owns 118,016 shares of the company's common stock.
Travere Therapeutics stock hits 52-week high at 67.97 USD By Investing.com
Travere Therapeutics Inc. stock recently reached a new 52-week high of $68.03, reflecting a 243% 1-year return. This surge follows strong Q2 revenue of $169.6 million, largely driven by its kidney drug FILSPARI, which saw a 96% increase in sales. Analyst firm Stifel raised its price target for Travere to $62 from $43, maintaining a Hold rating due to FILSPARI's robust performance.
Travere Therapeutics stock hits 52-week high at 67.97 USD By Investing.com
Travere Therapeutics (TVTX) stock reached a new 52-week high of $68.03, reflecting a 243% one-year return, driven by strong investor confidence and the success of its kidney drug, FILSPARI. The company reported Q2 revenue of $169.6 million, exceeding forecasts, with FILSPARI sales increasing by 96%. Stifel raised its price target for TVTX to $62, maintaining a Hold rating due to FILSPARI's strong performance.
Travere Therapeutics stock hits 52-week high at 66.35 USD
Travere Therapeutics (TVTX) stock reached a new 52-week high of $66.35, capping a significant rally with a 112% gain over six months and a 69% year-to-date return. This surge is fueled by strong Q2 2026 financial results, including revenue surpassing forecasts and a near doubling in sales for their kidney drug, FILSPARI. Despite trading above its InvestingPro Fair Value, analysts maintain price targets between $62 and $90, with Stifel raising its target to $62 due to FILSPARI's exceptional performance.
Travere Therapeutics stock hits 52-week high at 66.35 USD By Investing.com
Travere Therapeutics Inc (TVTX) stock reached a new 52-week high of $66.35, trading within 1% of this peak. This comes after the company reported strong Q2 2026 financial results, with revenue of $169.6 million, largely driven by the kidney drug FILSPARI, whose sales nearly doubled year-over-year. Stifel also raised its price target for Travere Therapeutics to $62, citing FILSPARI's exceptional performance following its FSGS launch.
Travere Therapeutics stock hits 52-week high at 66.35 USD By Investing.com
Travere Therapeutics (TVTX) stock reached a new 52-week high of $66.35, reflecting a 112% gain over six months and a 265.46% increase over the past year. This surge is largely driven by the strong performance of their kidney drug, FILSPARI, which helped the company exceed revenue forecasts in Q2 2026. Despite being considered overvalued by some analyses, analysts maintain price targets ranging from $62 to $90.
Travere Therapeutics (TVTX) Is Up 6.1% After FILSPARI Beats FSGS Launch Expectations
Travere Therapeutics (TVTX) saw its stock rise by 6.1% after its drug FILSPARI exceeded launch expectations for FSGS treatment, demonstrating broad physician demand among over 30,000 U.S. patients. The company is also advancing its rare disease pipeline with pegtibatinase for classical homocystinuria and civorebrutinib for multiple renal indications. This strong performance in FSGS is expected to reshape Travere's investment narrative, which is heavily focused on its kidney portfolio, and has led to a potential upside in its fair value estimates.
Travere Therapeutics (TVTX) Is Up 6.1% After FILSPARI Beats FSGS Launch Expectations
Travere Therapeutics (TVTX) saw its stock rise by 6.1% following news that its drug FILSPARI's launch for FSGS is exceeding expectations, driven by strong physician demand. This success reinforces the company's kidney-focused portfolio, which also includes a Phase III trial for pegtibatinase and the addition of civorebrutinib to its pipeline. While the strong launch boosts near-term growth, the article also notes the ongoing risk of heavy reliance on FILSPARI and increasing competition in the kidney disease market.
Travere Therapeutics (TVTX) director sells 10K shares under 10b5-1 plan
Travere Therapeutics (TVTX) director Gary A. Lyons exercised options for 10,000 shares and subsequently sold all 10,000 shares of common stock between August 17-18, 2026. The sales were conducted under a pre-arranged 10b5-1 trading plan adopted on May 18, 2026. Lyons acquired the shares at an exercise price of $17.44 per share and sold them in multiple tranches at weighted-average prices ranging from approximately $62.53 to $64.16 per share.
US High Growth Tech Stocks To Watch In August 2026
This article identifies top US high-growth tech stocks for August 2026, noting a flat market over the last week but a 19% rise over the past year. It highlights companies like Travere Therapeutics, AnaptysBio, and Coherent, detailing their growth ratings, revenue, earnings projections, and strategic developments. The analysis focuses on companies with robust growth potential and innovative approaches in their respective fields.
Travere Therapeutics (NASDAQ: TVTX) director plans 5,000-share sale tied to stock options
Travere Therapeutics director Gary Lyons plans to sell 5,000 shares of company common stock for an aggregate market value of $317,650.00, linked to the exercise of stock options. This sale, scheduled for August 18, 2026, follows a previous 10b5-1 sale of 5,000 shares on August 17, 2026, which generated $315,985.50. The transaction is being handled by Morgan Stanley Smith Barney.
US High Growth Tech Stocks To Watch In August 2026
This article identifies top US high-growth tech stocks for August 2026, noting the market's stability and expected earnings growth. It highlights companies like Travere Therapeutics, AnaptysBio, and Coherent, detailing their financial performance, growth potential, and strategic focus within their respective sectors, despite some currently being unprofitable. The analysis emphasizes innovative therapies and advanced technologies as key drivers for future profitability and market outperformance.
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline
Travere Therapeutics (NASDAQ:TVTX) is experiencing a stronger-than-expected launch for FILSPARI in FSGS, with broad physician demand and significant market potential. The company's IgA nephropathy business also continues to grow, contributing to a projected peak sales opportunity exceeding $3 billion. Additionally, Travere is advancing pegtibatinase in a Phase III trial for classical homocystinuria and expanding its renal pipeline with civorebrutinib, a new BTK inhibitor targeting primary membranous nephropathy, immune-mediated FSGS, and minimal change disease.
Travere Therapeutics, Inc. SEC Filing (Aug 17, 2026)
This article details a Form 144 SEC filing by Travere Therapeutics, Inc. (TVTX) on August 17, 2026. The filing indicates a proposed sale of 5,000 shares of common stock by an unnamed individual, acquired through the exercise of stock options on the same date, with an aggregate market value of $310,700.00. The transaction was handled by Morgan Stanley Smith Barney LLC and is expected to occur on NASDAQ.
S&CO Inc. Makes New Investment in Travere Therapeutics, Inc. $TVTX
S&CO Inc. has acquired a new stake of 56,000 shares in Travere Therapeutics, Inc. (NASDAQ:TVTX), valued at approximately $3.18 million. This investment comes as several other institutional investors have also adjusted their holdings in the company. Travere Therapeutics shares opened at $62.14, reflecting positive market sentiment and favorable analyst ratings, with an average price target of $61.67.
Travere Therapeutics (TVTX) Is Up 7.5% After Strong Q2 Revenue But Wider Net Loss - Has The Bull Case Changed?
Travere Therapeutics reported strong Q2 2026 revenue of US$169.58 million, a significant increase from the previous year, but also a wider net loss of US$34.8 million. The article discusses how this revenue growth, driven by its drug FILSPARI, reinforces the company's investment narrative focused on rare kidney diseases, despite ongoing losses from high R&D and commercial spending. Investors are urged to consider the balance between market traction and increasing costs, with analyst forecasts suggesting potential upside but also significant risks.
Travere Therapeutics (TVTX) sees Armistice Capital report 1.67% ownership in 13G/A
Armistice Capital and Steven Boyd have filed an amended Schedule 13G disclosing a 1.67% beneficial ownership stake in Travere Therapeutics (TVTX). This ownership translates to 1,572,539 shares of common stock, with shared voting and dispositive power, falling below the 5% reporting threshold for a passive investment. The shares are directly held by Armistice Capital Master Fund Ltd., with Armistice Capital acting as the investment manager.
Bank of America Corp DE Trims Position in Travere Therapeutics, Inc. $TVTX
Bank of America Corp DE has reduced its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 27.8% in the first quarter, selling over 500,000 shares while still retaining a significant holding. Despite this divestment, several other major institutional investors increased their positions in the biopharmaceutical company. Analyst sentiment remains largely positive, with a "Moderate Buy" consensus and an average price target of $61.67.
Travere Therapeutics (TVTX) Is Up 7.5% After Strong Q2 Revenue But Wider Net Loss - Has The Bull Case Changed?
Travere Therapeutics (TVTX) reported strong Q2 2026 revenue of US$169.58 million, up from US$114.45 million the previous year, but also a wider net loss of US$34.8 million. The company's investment narrative remains focused on the commercial traction of its rare kidney disease treatments, particularly FILSPARI, despite increased spending on R&D and commercialization. Analyst forecasts for 2029 project significant revenue and earnings growth, though some estimates are more conservative due to rising costs and competition.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics announced that its Compensation Committee granted inducement equity awards to 12 new employees. These grants consist of 38,940 restricted stock units (RSUs) of common stock, vesting over four years. The grants were made outside Travere's 2018 Equity Incentive Plan as inducements for new hires, in compliance with Nasdaq Listing Rule 5635(c)(4).
